The recognition of cancer-associated fucosylated antigens in colorectal cancer by a novel monoclonal antibody, YB-2.
A monoclonal antibody, YB-2, which has a novel epitope for fucosylated antigens and shows cross-reactivity with Y/Leb/H type 2 antigens, was used in an immunohistochemical study of human neoplastic and normal colorectal tissues. Of 64 colorectal cancers, 59 (92.2%) were stained by the YB-2 antibody; however, only 3 (12.0%) of 25 samples of normal colon mucosa and 13 (50.0%) of 26 adenomas expressed the antigens recognized by YB-2. Clinicopathologically, the YB-2-negative colon cancers were exclusively in Dukes stage A. These results indicate that the monoclonal antibody, YB-2, could detect cancer-associated antigens, and the degree of YB-2-reacted antigen expression might be correlated with the progression of colorectal carcinogenesis.
First Department of Surgery, Gunma University School of Medicine, Japan.
H
H
Naitoh
S
S
Yazawa
T
T
Asao
T
T
Nakajima
J
J
Nakamura
S
S
Takenoshita
Y
Y
Nagamachi
D000236:Adenoma / Q000276:immunology / Q000473:pathology; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000032:analysis*; D002277:Carcinoma / Q000276:immunology / Q000473:pathology; D015179:Colorectal Neoplasms / Q000276:immunology* / Q000473:pathology; D006801:Humans; D009367:Neoplasm Staging
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm